Glizid-MR 30 Tablet contains Gliclazide 30 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby enhancing glycemic control in patients with non-insulin-dependent diabetes. The modified-release formulation ensures a gradual and sustained release of the active ingredient, promoting stable blood glucose levels throughout the day and reducing the risk of hypoglycemia compared to immediate-release formulations. Glizid-MR 30 is typically prescribed as an adjunct to diet and exercise when these measures alone do not achieve adequate glycemic control. It is important to monitor blood glucose levels regularly to adjust the dosage appropriately and to minimize potential adverse effects such as hypoglycemia, gastrointestinal disturbances, or allergic reactions. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in elderly patients. Glizid-MR 30 should not be used in type 1 diabetes mellitus, diabetic ketoacidosis, or during pregnancy and lactation unless clearly indicated. Patient adherence to lifestyle modifications alongside pharmacotherapy is essential for optimal therapeutic outcomes.